REFERENCES
- Heare T, Hensley MA, Dell'Orfano S. Bone tumors: osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr. 2009;21:365–372.
- Meyer WH, Spunt SL. Soft tissue sarcomas of childhood. Cancer Treat Rev. 2004;30:269–80.
- Pappo AS, Parham DM, Rao BN, Soft tissue sarcomas in children. Semin Surg Oncol. 1999;16:121–143.
- Krishnan K, Khanna C, Helman LJ. The biology of metastases in pediatric sarcomas. Cancer J. 2005;11:306–313.
- Volker T, Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007;25:5435–5441.
- Meyer JS, Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2008;51:163–170.
- Nilsson G, The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res. 1999;59:3180–3184.
- Lidang Jensen M, Extraskeletal osteosarcomas: a clinicopathologic study of 25 cases. Am J Surg Pathol. 1998;22:588–594.
- Halpern BS, Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med. 2004;45:797–801.
- Kinahan PE, Hasegawa BH, Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med. 2003;33:166–179.
- Terasaki H, Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003;27:937–951.
- Hawkins DS, Evaluation of chemotherapy response in pediatric bone sarcomas by F-18]-fluorodeoxy-D-glucose positron emission tomography. Cancer. 2002;94:3277–3284.
- Folpe AL, (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279–1287.
- Evilevitch V, Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008;14:715–720.
- Benz MR, FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009;15:2856–2863.
- Benz MR, Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol. 2009;21:345–351.
- Benz MR, FDG-PET/CT imaging predicts histopathologic treatment responses after neoadjuvant therapy in adult primary bone sarcomas. Sarcoma. 2010:143540.
- Benz MR, Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med. 2010;51:1174–1181.
- Arush MW, Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer. 2007;49:901–905.
- Tateishi U, Accuracy of 18F fluorodeoxyglucose positron emission tomography/computed tomography in staging of pediatric sarcomas. J Pediatr Hematol Oncol. 2007;29:608–612.
- Mody RJ, FDG PET imaging of childhood sarcomas. Pediatr Blood Cancer. xxxx;54:222–2227.
- McCarville MB, PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol. 2005;184:1293–1304.
- Ben Arush MW, Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities. J Pediatr Hematol Oncol. 2006;28:440–445.
- Benz MR, Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008;49:1579–1584.
- Hawkins DS, F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 2009;115:3519–3525.